Mark A. Wilson was appointed Senior Vice President and General Counsel in December 2017. In this role, Mr. Wilson oversees all legal matters pertaining to the company, including contracts, corporate governance, securities law, SEC reporting, litigation, and all intellectual property matters including patent, copyright, and trademark matters. Mr. Wilson has over 20 years in the legal field, with a particular emphasis on intellectual property. Prior to his appointment as Nektar’s General Counsel in July 2016, Mr. Wilson led Nektar’s intellectual property department with oversight for the company's extensive patent portfolio, including the preparation and prosecution of patent applications.
Prior to joining Nektar in 2002, Mr. Wilson was an associate at Reed & Associates, a patent law firm in Menlo Park, California, where he successfully represented both early-stage and Fortune 500 companies.
Mr. Wilson received his J.D. from Seton Hall University, School of Law, and his B.S. in pharmacy from Rutgers University, College of Pharmacy. He is registered to practice before the U.S. Patent and Trademark Office and is a member of the California Bar.
What is Mark Andrew Wilson's net worth?
The estimated net worth of Mark Andrew Wilson is at least $868,870.92 as of August 16th, 2022. Mr. Wilson owns 281,188 shares of Nektar Therapeutics stock worth more than $868,871 as of February 5th. This net worth approximation does not reflect any other assets that Mr. Wilson may own. Learn More about Mark Andrew Wilson's net worth.
What is Mark Andrew Wilson's salary?
As the SVP of Nektar Therapeutics, Mr. Wilson earned a total compensation package of $3,503,661.00 in 2021. Mr. Wilson earned a salary of $500,000.00, stock awards of $1,707,078.00, options awards of $998,320.00, non-equity compensation of $287,500.00, and other compensation of $10,763.00. Learn More on Mark Andrew Wilson's salary.
How do I contact Mark Andrew Wilson?
Has Mark Andrew Wilson been buying or selling shares of Nektar Therapeutics?
Mark Andrew Wilson has not been actively trading shares of Nektar Therapeutics over the course of the past ninety days. Most recently, Mark Andrew Wilson sold 3,189 shares of the business's stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $4.76, for a transaction totalling $15,179.64. Following the completion of the sale, the senior vice president now directly owns 281,188 shares of the company's stock, valued at $1,338,454.88. Learn More on Mark Andrew Wilson's trading history.
Who are Nektar Therapeutics' active insiders?
Are insiders buying or selling shares of Nektar Therapeutics?
During the last year, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 314,077 shares worth more than $1,549,090.27. The most recent insider tranaction occured on November, 16th when insider Jonathan Zalevsky sold 13,460 shares worth more than $48,052.20. Insiders at Nektar Therapeutics own 3.4% of the company.
Learn More about insider trades at Nektar Therapeutics. Information on this page was last updated on 11/16/2022.
